Tubulis
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $361.8Mattributed |
|---|---|
| Latest round | series-c, $332.6M, 2025-10-15attributed |
| Founded | 2019 |
| Headquarters | Munich, Germany |
| Industry | biotech |
| Stage | series-b+ |
| Website | tubulis.com |
Tubulis develops antibody-drug conjugate therapeutics combining proprietary linker chemistry with new payloads for solid tumors. Patients with treatment-resistant solid tumors are the eventual target. Tubulis advances internal pipeline assets alongside partnerships with pharma companies.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-10-15 | series-c | $332.6M | undisclosed |
Detected tech stack
Apache HTTP Server, jQuery Migrate, Elementor 4.0.9, WordPress, PHP, MySQL, jquery 3.7.1, apache
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series C, $332.6M | attributed | sifted named as publisher. No document URL on file. |
| Total raised $361.8M | attributed | sifted named as publisher. No document URL on file. |
| Company existence | self-reported | tubulis.com, read 2026-05-07 |
| Description | self-reported | tubulis.com, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.